UNSPSC 51432501: Mecarbinate

This classification denotes an antihypertensive agent with the molecular formula C13H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z927X3UJ2W, chemically known as 1,2-dimethyl-3-carbethoxy- 5-hydroxyindole but generally known as mecarbinate, which bears US NIH Compound Identifier 616236. European Medicines Agency schedules Mecarbinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08671MIG.

UNSPSC 51432501 Mecarbinate is a Commodity code covering pharmaceutical active ingredients and finished medications used in emergency medical services, hospital formularies, and state pharmacy benefit programs. State and local governments procure under this code primarily through municipal fire and rescue departments acquiring emergency medications; state health and human services agencies managing pharmacy benefit programs and direct-to-manufacturer prescription initiatives; and multistate cooperative purchasing alliances sourcing generic pharmaceuticals for distribution across participating jurisdictions. The work includes supply of specific medications with defined unit quantities, expiration-date requirements (typically nine months or more from acceptance), and rapid fulfillment timelines (often ten calendar days from order). Vendors must demonstrate compliance with current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) requirements, FDA standards, OSHA Hazard Communication Standards for Safety Data Sheets, and Section 508 accessibility documentation. Pricing models vary from firm fixed-price with freight-on-board delivery to net pricing and WAC-minus structures, and contracts typically span one to two years with renewal or extension options.

The City of Tampa's Purchasing Department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent recent activity under this code. Tampa Fire Rescue's Advanced Life Support Medications IFB (26P00188, due April 8, 2026, estimated contract value $40,000) solicited 370 units of Labetalol, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem with a Small Local Business Enterprise sheltered-market designation and 5 percent bid discount. Texas HHS issued an RFI (HHS0017013, closed April 3, 2026) exploring vendor capacity for direct-to-manufacturer prescription programs serving state employee and retiree plans outside traditional pharmacy benefit manager channels. MMCAP's RFP (S1070000015802, due March 26, 2026) sought generic multi-source pharmaceutical manufacturers to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) effective July 1, 2026, with pricing weighted 75 percent in evaluation and vendor agreements extending through June 30, 2028. Recent activity concentrates in Florida, Texas, and Minnesota, with multistate cooperative purchasing extending to Oregon.